Compare TSN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSN | NTRA |
|---|---|---|
| Founded | 1935 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 27.0B |
| IPO Year | N/A | 2015 |
| Metric | TSN | NTRA |
|---|---|---|
| Price | $56.86 | $244.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $61.70 | ★ $227.69 |
| AVG Volume (30 Days) | ★ 3.7M | 1.7M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $54,441,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | $4.28 | $32.77 |
| Revenue Next Year | $0.76 | $16.51 |
| P/E Ratio | $42.87 | ★ N/A |
| Revenue Growth | 2.12 | ★ 38.17 |
| 52 Week Low | $50.56 | $125.38 |
| 52 Week High | $64.36 | $245.59 |
| Indicator | TSN | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 80.03 |
| Support Level | $52.65 | $233.67 |
| Resistance Level | $58.67 | $240.18 |
| Average True Range (ATR) | 1.27 | 7.39 |
| MACD | 0.14 | 0.68 |
| Stochastic Oscillator | 69.93 | 97.49 |
Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, each composing about one third of US sales. Prepared foods constituted 18% of fiscal 2024 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.